SCHEMBL4823754

SCHEMBL4823754

CN(C)CCN(Cc1ccccc1)Cc1cccc(Cl)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 1/20 0.62
CAMKK2 Q96RR4 1/20 0.62
TAAR1 Q96RJ0 3/20 0.60
TSHR P16473 3/20 0.53
RECQL P46063 1/20 0.53
GAA P10253 1/20 0.50
PYCR1 P32322 1/20 0.49
AOC3 Q16853 1/20 0.49
HTT P42858 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
BCHE P06276 1/20 0.46
ACHE P22303 1/20 0.46
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.45
RIPK1 Q13546 1/20 0.43
POLB P06746 1/20 0.43
TMEM97 Q5BJF2 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
TAS2R14 Q9NYV8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13061026 0.88 TAAR1 (0.57) CALM1CAMKK2TAAR1TSHRRECQL
SCHEMBL524817 0.84 CALM1 (0.65) CALM1CAMKK2TAAR1TSHRAOC3
SCHEMBL13005692 0.84 TSHR (0.54) CALM1CAMKK2TAAR1TSHRRECQL
SCHEMBL4823046 0.83 CALM1 (0.57) CALM1CAMKK2TSHRPYCR1HTT
SCHEMBL4821016 0.82 CALM1 (0.54) CALM1CAMKK2TAAR1TSHRRECQL
SCHEMBL13061102 0.82 CALM1 (0.64) CALM1CAMKK2TAAR1TSHRHTT
SCHEMBL10039143 0.82 CALM1 (0.64) CALM1CAMKK2TAAR1TSHRRECQL
SCHEMBL14181862 0.81 CALM1 (0.62) CALM1CAMKK2TAAR1TSHRPYCR1
SCHEMBL18157879 0.80 CALM1 (0.65) CALM1CAMKK2TAAR1TSHRAOC3
SCHEMBL8290710 0.79 TAAR1 (0.66) TAAR1TSHRRECQLGAAPYCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269217-A1 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-10-30 US disclosed
US-20080269217-A1 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-10-30 US disclosed
US-20080269217-A1 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-10-30 US disclosed
US-7375125-B2 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-05-20 US disclosed
US-7375125-B2 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-05-20 US disclosed
US-7375125-B2 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-05-20 US disclosed
US-6699873-B1 EATING DISORDERS MILLENNIUM PHARMACEUTICALS, INC. 2004-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269217-A1 Melanocortin-4 receptor binding compounds and methods of use thereof MC4R, MC5R, MC3R CALM1 3048/4885CAMKK2 2321/4885TAAR1 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.